The Finasteride Riddle
January 2014
in “
ScholarWorks - University of Montana (University of Montana)
”
TLDR Finasteride reduces low-grade prostate cancer but may not be beneficial overall.
The study on finasteride, originally aimed at reducing prostate cancer incidence, revealed a paradox: it decreased low-grade prostate cancer but seemingly increased high-grade disease. Due to these mixed outcomes, the FDA did not approve finasteride for cancer prevention. Follow-up data suggested that concerns about finasteride's risks might have been overstated, yet it did not demonstrate a reduction in mortality. Although finasteride could potentially aid in reducing overdiagnosis in PSA testing, other associated harms questioned its utility even in this secondary role.